# 

#### **Endocrine!**



Male Hypogonadism	Female Hypogonadism	PCOS	Transgender
<u>100</u>	<u>100</u>	<u>100</u>	<u>100</u>
<u>200</u>	<u>200</u>	<u>200</u>	<u>200</u>
<u>300</u>	<u>300</u>	<u>300</u>	<u>300</u>
<u>400</u>	<u>400</u>	<u>400</u>	400
500 PPTBackgrounds.net	<u>500</u>	<u>500</u>	<u>500</u>


 58 yo M presents with fatigue and low libido so his PCP obtained an 8AM total testosterone level which came back 280 (300-800).

• What is the next diagnostic step?




Repeat AM testosterone level

#### Evaluation of the male with possible hypogonadism



#### Diurnal pattern of testosterone secretion



• You decide to treat your hypogonadal patient with testosterone.

 What 2 essential lab tests do you monitor while a patient is on testosterone replacement therapy (TRT)?



• CBC and PSA



 Total testosterone level – generally target between 300-800 (depending on the age)

 CBC – TRT stimulates production of RBCs so Hb & Hct should be checked to ensure HCT is not > 54

 PSA – TRT increases PSA which leads to theoretical risk of prostate cancer

#### **Summary of Recommendations**

#### +1.0 Diagnosis of Hypogonadism in Men

+2.0 Treatment of Hypogonadism with Testosterone

#### -3.0 Monitoring of Testosterone Replacement Therapy

**3.1** In hypogonadal men who have started testosterone therapy, we recommend evaluating the patient after treatment initiation to assess whether the patient has responded to treatment, is suffering any adverse effects, and is complying with the treatment regimen. (Ungraded Good Practice Statement)

3.2 We recommend a urological consultation for hypogonadal men receiving testosterone treatment if during the first 12 months of testosterone treatment there is a confirmed increase in prostate specific antigen concentration >1.4 ng/mL above baseline, a confirmed prostatespecific antigen >4.0 ng/mL, or a prostatic abnormality detected on digital rectal examination. After 1 year, prostate monitoring should conform to standard guidelines for prostate cancer screening based on the race and age of the patient. (2 |⊕⊕OO)





• List 3 potential side effects of testosterone replacement therapy (TRT).



- Infertility!!!
- Erythrocytosis  $\rightarrow$  cardiovascular risk
- Acne
- Agitation
- Hypertension  $\rightarrow$  cardiovascular risk
- Worsens sleep apnea
- (Theoretical) BPH, prostate cancer



 List 4 signs and/or symptoms of male hypogonadism.



- Low energy
- Low libido
- Decreased muscle mass
- Decreased body/facial hair
- Small testes
- Gynecomastia



You diagnose your male patient with secondary hypogonadism.

 List 5 diagnostic tests you would perform to evaluate for secondary causes.




- MRI Brain
- TSH + FT4
- PRL
- Sleep study
- Hba1c
- Iron studies
- 8AM cortisol level
- IGF-1



- Other things:
  - Obesity
  - Opioid use
  - Difficulty having children
  - Testicular trauma or infection
  - History of traumatic brain injury
  - History of head radiation
  - Age





tubule

PPTBACKGROUNDS.NET

#### Causes of hypogonadotropic (secondary) hypogonadism

Acquired	
Tumors	
Benign tumors and cysts	
Craniopharyngiomas	
Germinomas, meningiomas, gliomas, astrocytomas	
Metastatic tumors (breast, lung, prostate)	
"Functional" gonadotropin deficiency	
Chronic systemic disease	
Acute illness	
Malnutrition	
Hypothyroidism, hyperprolactinemia, diabetes mellitus, Cushing's disease	
Anorexia nervosa, bulimia	
Post-androgen abuse	
Infiltrative diseases	
Hemochromatosis	
Granulomatous diseases	
Histiocytosis	
Head trauma	
Pituitary apoplexy	
Drugs - marijuana, opioids, anabolic steroids	

\*\*\*

 Diagnosis of a woman younger than 40 years with irregular menses and elevated FSH in menopausal range.



 Primary ovarian insufficiency, "premature ovarian failure"



List 2 treatment options for menopausal symptoms (vasomotor).



Hormone replacement therapy

• SSRI's – venlafaxine, fluoxetine, paroxetine

Gabapentin



 List 3 causes of functional hypothalamic amenorrhea.



- Over exercise
- Weight loss, anorexia nervosa or bulimia
- Severe Depression
- End Stage of Chronic disease



 What is the most important test that you will order during initial evaluation for amenorrhea in a young woman.



• HCG first to rule out pregnancy



- Others
- If hyperandrogenism, can order total testosterone, DHEAS, and 17-OH progesterone
- Prolactin
- LH + FSH
- Estradiol
- TSH
- Pelvic ultrasound



 List 5 physiologic changes that accompany menopause.



- Loss of bone calcium---osteoporosis
- Increased rates of CAD
- Skin and vaginal atrophy
- Hot flashes
- Dyslipidemia increased Tg's and LDL, decreased HDL
  - Thought to contribute to increased cardiovascular risk
- Sleep disturbance
- Depression

 A 26 yo F presents for assistance with weight loss. She mentions that she has been having periods every 3-4 months and on exam she has increased facial hair as well as acanthosis nigricans.

 What additional test (if needed) is required to diagnose PCOS?




 None – she has oligomenorrhea and clinical signs of hyperandrogenism




- PCOS is primarily a clinical diagnosis but per Rotterdam criteria (2003), you need 2 of 3:
  - Oligo- or anovulation
  - Clinical and/or biochemical signs of hyperandrogenism
  - Polycystic ovaries (ultrasound)




- Serum total testosterone can be measured a level > 45 ng/dL suggests biochemical evidence of hyperandrogenism
  - Type of lab matters, LC-MS/MS (liquid chromatography), +/- measuring free testosterone
- Transvaginal ultrasound
  12+ follicles in each ovary



#### Clinical Signs of Androgen Excess: Alopecia, Hirsutism, Acne





In androgen excess, androgen-sensitive hair follicles shorten during anagen phase



 A 34-yo F is evaluated after inability to conceive for 13 months without success. She was recently diagnosed with PCOS.

 Name 1 treatment option that can help her become pregnant.




• Treatment options:

Clomiphene (selective estrogen receptor modulator)

 Letrozole (aromatase inhibitor) – per ACOG 2018 is first line

Gonadotropins is second line for PCOS





 A 30 yo woman diagnosed with PCOS desires treatment for her hirsutism.

• What hormonal treatments can you offer?



- OCP's
- Spironolactone



 List at least 3 metabolic consequences of PCOS



- Obesity
- Insulin resistance/diabetes
- Hyperlipidemia
- Hypertension
- NASH
- Metabolic Syndrome




		P		
Non-PCOS	PCOS	Value	HR	95% CI
25 660	2566			
943 (3.7)	411 (16.0)	<.001	4.71	4.19-5.28
980 (3.8)	321 (12.5)	<.001	2.84 <sup>a</sup>	2.49-3.23
1873 (7.3)	521 (20.3)	<.001	2.96 <sup>a</sup>	2.69-3.27
	. ,			
192 (0.7)	98 (3.8)	<.001	3.20 <sup>a</sup>	2.47-4.13
50 (0.2)	21 (0.8)	<.001	2.89 <sup>a</sup>	1.68-4.97
51 (0.2)	15 (0.6)	.002	2.58ª	1.43-4.67
266 (1.0)	44 (1.7)	.013	1.49 <sup>a</sup>	1.09-2.05
1497 (5.8)	275 (10.7)	<.001	1.81 <sup>a</sup>	1.59-2.05
1160 (4.5)	271 (10.6)	<.001	2.51	2.18-2.88
3635 (14.2)	585 (22.8)	<.001	1.67	1.53-1.82
4167 (16.2)	661 (25.8)	<.001	1.55ª	1.43-1.68
1525 (5.9)	358 (14.0)	<.001	2.50	2.19-2.76
1116 (4.3)	252 (9.8)	<.001	2.32	2.03-2.67
	25 660 943 (3.7) 980 (3.8) 1873 (7.3) 192 (0.7) 50 (0.2) 51 (0.2) 266 (1.0) 1497 (5.8) 1160 (4.5) 3635 (14.2) 4167 (16.2) 1525 (5.9)	25 660      2566        943 (3.7)      411 (16.0)        980 (3.8)      321 (12.5)        1873 (7.3)      521 (20.3)        192 (0.7)      98 (3.8)        50 (0.2)      21 (0.8)        51 (0.2)      15 (0.6)        266 (1.0)      44 (1.7)        1497 (5.8)      275 (10.7)        1160 (4.5)      271 (10.6)        3635 (14.2)      585 (22.8)        4167 (16.2)      661 (25.8)        1525 (5.9)      358 (14.0)	Non-PCOSPCOSValue25 6602566943 (3.7)411 (16.0)980 (3.8)321 (12.5)980 (3.8)321 (12.5)1873 (7.3)521 (20.3)192 (0.7)98 (3.8) $50 (0.2)$ 21 (0.8)21 (0.8)<.001	Non-PCOSPCOSValueHR25 6602566943 (3.7)411 (16.0)<.001

Hart R et al. JCEM 2015; 100(3):911-9 Dube R. Avicenna J Med. 2016; 6(4): 91-102



#### Identify this scale



Ferriman-Gallwey Score



 A 28 yo birth female mentioned that she feels like male since 5 years old and wishes to undergo replacement hormone therapy. What medication would you start for this transmale?



Table 2. Hormonal Regimens Regularly Used in Transmen				
Testosterone	Recommended dose			
Intramuscular enanthate or cypionate*	100–200 mg/2 weeks			
Intramuscular mixed esters (Sustanon®) Intramuscular undecanoate	250 mg/2-3 weeks 1000 mg/12 weeks OR 750 mg / 8 weeks**			
Testosterone gel	25-100 mg/day			
Testosterone patch	2 or 4 mg/day			

Generally target T levels in a normal male level for the same age

What are 2 hormonal treatment options for transwomen?



Table 1. Hormonal Regimens Regularly Used in Transwomen				
Estrogens	Recommended Dose			
Oral estradiol	2-6 mg daily			
Intramuscular estradiol valerate/cypionate	10-20 mg/1-2 weeks			
Estradiol patch*	50-100 mcg/24 hours			
Estradiol gel*	0.75 mg-2.25 mcg daily			
Antiandrogens**				
Cyproterone acetate	10-50 mg daily			
Spironolactone	50-200 mg daily			
GnRH analogue	Varies per preparation			

- Generally target premenopausal E2 levels (100-200)
- If postmenopausal, no specific guidelines but I generally target between 60-100
- Older patients are at greater risk of experiencing adverse effects of E2



 A 55 yo MTF transgender wishes to undergo hormone replacement therapy with estradiol but expresses concern about increased risk of VTE.

What hormone replacement therapy would be preferable in this case?

• Estradiol patch or injection

• List 4 physical changes in a transwoman undergoing hormone replacement therapy.



- Softening of the skin (variable)
- Decreased muscle mass and strength (years)
- Fat redistribution (years)
- Decreased hair growth (years)
- Decreased sexual desire (6 months)
- Breast growth (6 mo 2 years)
- Decreased erections (6 months)
- Decreased sperm production (months to years)

• List 5 physical changes in a transman undergoing hormone replacement therapy.





- Skin oiliness/acne (6 months)
- Increased muscle mass and strength (years)
- Deepened voice (1-2 years)
- Fat distribution (years)
- Body and facial hair growth (years)
- Cessation of menses (variable)
- Clitoral enlargement (1-2 years)
- Vaginal atrophy (1-2 years)